Effects of ketotifen on insulin resistance in high-carbon hydrate-fat diet rats

Abstract

Abstract: AIM: To investigate the effects of ketotifen on insulin resistance in high-carbon hydrate-fat diet wistar rats. METHODS: Male SD rats were randomly divided into three groups: group A (basal diet), group B (high-carbon hydrate-fat diet), group C (high-carbon hydrate-fat diet and ketotifen). And then the body weights, fasting blood glucose (FBG), fasting insulin (FINS) , riglyceride (TG) and low density lipoprotein cholesterin (LDL-C), interleukin-6 (IL-6) and tumor nectosis factor-α (TNF-α) in serum and liver were measured. RESULTS:Compared with group A, the body weights, FBG and FINS of group B significantly were increased (P<0.05). Compared with group B, the insulin sensitivity index (ISI) and hepatic glycogen levels of group C significantly were increased (P<0.05), the body weights, FBG, FINS, TG and LDL-C levels, IL-6 and TNF-α levels in serum and liver were reduced (P<0.05). CONCLUSION: Ketotifen can ameliorate insulin resistance in high-carbon hydrate-fat diet wistar rats by reducing the body inflammatory reaction.

Key words: ketotifen, mast cell, insulin resistance, IL-6, TNF-α

CLC Number:

R965.2

ZOU Liu-yi, WANG Mei-rong, NI Lian-song. Effects of ketotifen on insulin resistance in high-carbon hydrate-fat diet rats[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(7): 761-765.

References

[1] Wellen KE,Hotamisligil GS.Inflammation,stress and diabetes[J]. J Clin Invest, 2005, 115(5): 1111-1119.
[2] Lundequist A, Pejler G.Biological implications of preformed mast cell mediators[J]. Cell Mol Life Sci, 2011, 68(6): 965-975.
[3] Wang J, Shi GP.Mast cell stabilization: novel medication for obesity and diabetes[J]. Diabetes Metab Res Rev, 2011, 27(8): 919-924.
[4] Wu RL, Anthes JC, Kreutner W, et al.Desloratadine inhibits constitutive and histamine-stimulated nuclear factor-kappaB activity consistent with inverse agonism at the histamine H1 Recepto[J]. Int Arch Allergy Immunol, 2004, 135(4): 313-318.
[5] Galli SJ, Tsai M.IgE and mast cells in allergic disease[J]. Nat Med, 2012, 18(5): 693-704.
[6] Zhang J, Shi GP.Mast cells and metabolic syndrome[J]. Biochim Biophys Acta, 2012, 1822(1): 14-20.
[7] Sun J, Sukhova GK, Wolters PJ, et al.Mast cells promote atherosclerosis by releasing proinflammatory cytokines[J]. Nat Med, 2007, 13(6): 719-724.
[8] Wang Z, Zhang H, Shen XH, et al.Immunoglobulin E and mast cell proteases are potential risk factors of human pre-diabetes and diabetes mellitus[J]. PLoS One, 2011, 6(12): e28962.
[9] Divoux A, Moutel S, Poitou C, et al.Mast cells in human adipose tissue: link with morbid obesity, inflammatory status, and diabetes[J]. J Clin Endocrinol Metab, 2012, 97(9): E1677-E1685.
[10] Liu J, Divoux A, Sun J, et al.Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice[J]. Nat Med, 2009, 15(8): 940-945.
[11] Clore JN, Stillman J, Sugerman H.Glucose-6-phosphatase flux in vitro is increased in type 2 diabetes[J]. Diabetes, 2000, 49(6): 969-974.
[12] Fernandez-Real JM, Vayreda M, Richart C, et al.Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women[J]. J Clin Endocrinol Metab, 2001, 86(3): 1154-1159.
[13] Bastard JP, Maachi M, Van Nhieu JT, et al.Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro[J]. J Clin Endocrinol Metab, 2002, 87(5): 2084-2049.
[14] Plomgaard P, Nielsen AR, Fischer CP, et al.Associations between insulin resistance and TNF-alpha in plasma, skeletal muscle and adipose tissue in humans with and without type 2 diabetes[J]. Diabetologia, 2007, 50(12): 2562-2571.

[1]	WANG Tiefeng, SU Jie, WANG Weidong, XIA Rongshuang, LI Sifan, ZHU Wenrui, LOU Zhaohuan. Mechanisms of Radix Tetrastigma on anti rheumatoid arthritis via regulating the balance of Th17/Treg [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 138-146.
[2]	QUAN Haiyan, JIANG Xing, HE Lu. Recent progress of mitophagy in hepatic insulin resistance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 198-204.
[3]	CAI Jiangyi, LIU Yao, LI Jiacheng. Temperature selection of intravesical sodium hyaluronate in the treatment of interstitial cystitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 447-454.
[4]	YU Jiaojiao, YANG Yang, LIU Ying, GUO Xiaoxi, XU Tianrui, AN Shu. Paeoniflorin inhibits mast cell activation and degranulation through PI3K/AKT/m-TOR signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 961-968.
[5]	QUAN Haiyan, LIU Yuhuan, YANG Li, YANG Fang, QIN Xuping. Improvement of CGRP on vascular endothelial cells insulin resistance via activation of cAMP/PPARγ/eNOS pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(6): 615-622.
[6]	DING Fan, LI Wenxiong, ZHANG Jiali, ZHANG Yan. Research progress on pathology mechanism and treatment target for diabetic sarcopenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(12): 1428-1433.
[7]	ZHENG Li, MO Juanfen, WU Jiayuan, GUO Li, BAO Yi. Study on the anti-hyperlipidemia mechanisms and signaling pathways of traditional Chinese medicine Polygonum cuspidatum based on network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(10): 1107-1119.
[8]	WANG Jing, ZHOU Haibin, GU Weigang, WANG Xia, YANG Jianfeng. Effect of ketotifen on gastrointestinal symptoms, visceral sensitivity and intestinal mast cells in patients with irritable bowel syndrome with diarrheal [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 63-70.
[9]	LU Wei, ZHOU Bingrong,TANG Yi, FAN Yibin, TAO Xiaohua. Role of Th17 cells in acne pathogenesis and the correlation with severity of acne [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(1): 83-87.
[10]	SONG Meiqing. Effect of metformin on bone mineral density, insulin resistance and cytokines in type 2 diabetes mellitus patients with primary hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(6): 694-698.
[11]	ZHANG Xinmin, CHEN Peng, YE Sheng, XIA Wujie, LI Yuechun. Proteasome inhibitors decrease IL-6 and TNF-α levels in mouse acute viral myocarditis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(4): 406-411.
[12]	CHEN Fei-fei, QIAN Jia-shu, WANG Liang-rong, JIN Li-da, XIONG Xiang-qing. Protective effect of shenmai injection on mechanical ventilation associated lung injury in patients with one-lung ventilation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(2): 199-202.
[13]	SHEN Ji-zhong, LIU Hang. Experimental study of a metabolic syndrome mouse model induced by high sucrose-containing drinking water [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(9): 1011-1015.
[14]	CHEN Zi-miao,WANG Mei-rong,YE Ting-ting,GU Xue-jiang CHEN Xiong, ZHU Hong, NI Lian-song. Antiobesity effect of ketotifen in high-carbon hydrate-fat diet induced obese rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(1): 23-28.
[15]	CHEN Zi-miao, CHEN Xiao-jun, WANG Mei-rong, PAN Liang-liang, HU Wan-li, NI Lian-song. Effect of Ketotifen on pancreatic function of streptozotocin-induced type 2 diabetic rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(6): 627-632.